Modulation of food consumption and sleep-wake cycle in mice by the neutral CB1 antagonist ABD459

Behavioural Pharmacology

Volumn 26, Issue 3, 2015, Pages 289-303

  Goonawardena, Anushka V ^a   Plano, Andrea ^b   Robinson, Lianne ^b   Ross, Ruth ^c   Greig, Iain ^b   Pertwee, Roger G ^b   Hampson, Robert E ^a,b   Platt, Bettina ^b   Riedel, Gernot ^a,b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

agonist WIN 2; antagonist AM251; cannabinoid receptor 1 receptors; cannabinoids; electroencephalogram; endocannabinoid; mouse; neutral antagonist ABD459; nonrapid eye movement sleep; rapid eye movement sleep

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3-(2-HYDROXY-4-(1,1-DIMETHYLHEPTYL)PHENYL)-4-(3-HYDROXYPROPYL)CYCLOHEXANOL; 5-(4-BROMOPHENYL)-1-(2,4-DICHLOROPHENYL)-4-METHYLPYRAZOL-3-YL) 4-METHOXYPHENYL METHANONE; BENZOXAZINE DERIVATIVE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CYCLOHEXANOL DERIVATIVE; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; C57BL MOUSE; DRUG EFFECTS; ELECTROENCEPHALOGRAPHY; FEEDING BEHAVIOR; MALE; METABOLISM; MOTOR ACTIVITY; MOUSE; REM SLEEP; SLEEP; WAKEFULNESS;

ANIMALS; BENZOXAZINES; BRAIN; CANNABINOID RECEPTOR ANTAGONISTS; CYCLOHEXANOLS; ELECTROENCEPHALOGRAPHY; FEEDING BEHAVIOR; MALE; MICE; MICE, INBRED C57BL; MORPHOLINES; MOTOR ACTIVITY; NAPHTHALENES; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; SLEEP; SLEEP, REM; WAKEFULNESS;

EID: 84940001134     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0000000000000108     Document Type: Article

References (81)

1. André A, Gonthier MP (2010). The endocannabinoid system: its roles in energy balance and potential as a target for obesity treatment. Int J Biochem Cell Biol 42:1788-1801.
2. Babiloni C, Marzano N, Lizio R, Valenzano A, Triggiani AI, Petito A, et al. (2011). Resting state cortical electroencephalographic rhythms in subjects with normal and abnormal body weight. Neuroimage 58:698-707.
3. Blanco-Centurion C, Xu M, Murillo-Rodriguez E, Gerashchenko D, Shiromani AM, Salin-Pascual RJ, et al. (2006). Adenosine and sleep homeostasis in the basal forebrain. J Neurosci 26:8092-8100.
4. Blasio A, Iemolo A, Sabino V, Petrosino S, Steardo L, Rice KC, et al. (2013). Rimonabant precipitates anxiety in rats withdrawn from palatable food: role of the central amygdala. Neuropsychopharmacology 38:2498-2507.
5. Brankack J, Platt B, Riedel G (2009). Sleep and hippocampus: do we search for the right things? Prog Neuropsychopharmacol Biol Psychiatry 33:806-812.
6. Buonamici M, Young GA, Khazan N (1982). Effects of acute delta 9-THC administration on EEG and EEG power spectra in the rat. Neuropharmacology 21:825-829.
7. Chambers AP, Vemuri VK, Peng Y, Wood JT, Olszewska T, Pittman QJ, et al. (2007). A neutral CB1 receptor antagonist reduces weight gain in rat. Am J Physiol Regul Integr Comp Physiol 293:R2185-R2193.
8. Cheng Y, Prusoff WH (1973). Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
9. Chowdhury U, Gordon I, Lask B, Watkins B, Watt H, Christie D (2003). Earlyonset anorexia nervosa: is there evidence of limbic system imbalance? Int J Eat Disord 33:388-396.
10. Clarke JR, Rossato JI, Monteiro S, Bevilaqua LR, Izquierdo I, Cammarota M (2008). Posttraining activation of CB1 cannabinoid receptors in the CA1 region of the dorsal hippocampus impairs object recognition long-term memory. Neurobiol Learn Mem 90:374-381.
11. Cluny NL, Vemuri VK, Chambers AP, Limebeer CL, Bedard H, Wood JT, et al. (2010). A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents. Br J Pharmacol 161:629-642.
12. Cluny NL, Chambers AP, Vemuri VK,Wood JT, Eller LK, Freni C, et al. (2011). The neutral cannabinoid CB1 receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat. Pharmacol Biochem Behav 97:537-543.
13. Cota D, Tschöp MH, Horvath TL, Levine AS (2006). Cannabinoids, opioids and eating behavior: the molecular face of hedonism? Brain Res Rev 51:85-107.
14. D'Souza DC, Fridberg DJ, Skosnik PD, Williams A, Roach B, Singh N, et al. (2012). Dose-related modulation of event-related potentials to novel and target stimuli by intravenous 9-THC in humans. Neuropsychopharmacology 37:1632-1646.
15. Del Parigi A, Gautier JF, Chen K, Salbe AD, Ravussin E, Reiman E, Tataranni PA (2002). Neuroimaging and obesity: mapping the brain responses to hunger and satiation in humans using positron emission tomography. Ann NY Acad Sci 967:389-397.
16. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949.
17. Engeli S (2012). Central and peripheral cannabinoid receptors as therapeutic targets in the control of food intake and body weight. Handb Exp Pharmacol 209:357-381.
18. Feinberg I, Jones R, Walker JM, Cavness C, March J (1975). Effects of high dosage delta-9-tetrahydrocannabinol on sleep patterns in man. Clin Pharmacol Ther 17:458-466.
19. Feinberg I, Jones R, Walker J, Cavness C, Floyd T (1976). Effects of marijuana extract and tetrahydrocannabinol on electroencephalographic sleep patterns. Clin Pharmacol Ther 19:782-794.
20. Freemon FR (1982). The effect of chronically administered delta-9-tetrahydrocannabinol upon the polygraphically monitored sleep of normal volunteers. Drug Alcohol Depend 10:345-353.
21. Freemon FR, Salinas-Garcia RF,Ward JW (1974). Sleep patterns in a patient with a brain stem infarction involving the raphe nucleus. Electroencephalogr Clin Neurophysiol 36:657-660.
22. Gautier JF, Chen K, Salbe AD, Bandy D, Pratley RE, Heiman M, et al. (2000). Differential brain responses to satiation in obese and lean men. Diabetes 49:838-846.
23. Goonawardena AV, Robinson L, Hampson RE, Riedel G (2010a). Cannabinoid and cholinergic systems interact during performance of a short-term memory task in the rat. Learn Mem 17:502-511.
24. Goonawardena AV, Robinson L, Riedel G, Hampson RE (2010b). Recruitment of hippocampal neurons to encode behavioral events in the rat: alterations in cognitive demand and cannabinoid exposure. Hippocampus 20:1083-1094.
25. Goonawardena AV, Riedel G, Hampson RE (2011a). Cannabinoids alterspontaneous firing, bursting, and cell synchrony of hippocampal principal cells. Hippocampus 21:520-531.
26. Goonawardena AV, Sesay J, Sexton CA, Riedel G, Hampson RE (2011b). Pharmacological elevation of anandamide impairs short-term memory by altering the neurophysiology in the hippocampus. Neuropharmacology 61 (5-6):1016-1025.
27. Goonawardena AV, Plano A, Robinson L, Platt B, Hampson RE, Riedel G (2011c). A pilot study into the effects of CB1 cannabinoid receptor agonist, WIN55,212-2 or the antagonist/inverse agonist AM251 on sleep in rats. Sleep disorders. 2011:178469.
28. Gottesmann C (2002). GABA mechanisms and sleep. Neuroscience 111:231-239.
29. Hampson RE, Deadwyler SA (1999). Cannabinoids, hippocampal function and memory. Life Sci 65:715-723.
30. Hampson RE, Simeral JD, Kelly EJ, Deadwyler SA (2003). Tolerance to the memory disruptive effects of cannabinoids involves adaptation by hippocampal neurons. Hippocampus 13:543-556.
31. Hodge J, Bow JP, Plyler KS, Vemuri VK, Wisniecki A, Salamone JD, et al. (2008). The cannabinoid CB1 receptor inverse agonist AM 251 and antagonist AM 4113 produce similar effects on the behavioral satiety sequence in rats. Behav Brain Res 193:298-305.
32. Hoffman LD, Polich J (1998). EEG, ERPs and food consumption. Biol Psychol 48:139-151.
33. Howlett AC (1995). Pharmacology of cannabinoid receptors. Annu Rev Pharmacol Toxicol 35:607-634.
34. Hurst DP, Lynch DL, Barnett-Norris J, Hyatt SM, Seltzman HH, Zhong M, et al. (2002). N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. Mol Pharmacol 62:1274-1287.
35. Hurst D, Umejiego U, Lynch D, Seltzman H, Hyatt S, Roche M, et al. (2006). Biarylpyrazole inverse agonists at the cannabinoid CB1 receptor: importance of the C-3 carboxamide oxygen/lysine3.28(192) interaction. J Med Chem 49:5969-5987.
36. Jacobson LH, Commerford SR, Gerber SP, Chen YA, Dardik B, Chaperon F, et al. (2011). Characterization of a novel, brain-penetrating CB1 receptor inverse agonist: metabolic profile in diet-induced obese models and aspects of central activity. Naunyn Schmiedebergs Arch Pharmacol 384:565-581.
37. Jagerovic N, Hernandez-Folgado L, Alkorta I, Goya P, Navarro M, Serrano A, et al. (2004). Discovery of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1h-1,2,4-triazole, a novel in vivo cannabinoid antagonist containing a 1,2,4-triazole motif. J Med Chem 47:2939-2942.
38. Jáuregui-Lobera I (2012). Electroencephalography in eating disorders. Neuropsychiatric Dis Treat 8:1-11.
39. Jones D (2008). End of the line for cannabinoid receptor 1 as an anti-obesity target? Nat Rev Drug Discov 7:961-962.
40. Jyoti A, Plano A, Riedel G, Platt B (2010). EEG, activity, and sleep architecture in a transgenic AbetaPPSWE/PSEN1A246E Alzheimer's disease mouse. J Alzheimers Dis 22:873-887.
41. Kang JG, Park CY (2012). Anti-obesity drugs: a review about their effects and safety. Diabetes Metab J 36:13-25.
42. Kirkham TC, Williams CM (2001). Endogenous cannabinoids and appetite. Nutr Res Rev 14:65-86.
43. Koban M, Sita LV, Le WW, Hoffman GE (2008). Sleep deprivation of rats: the hyperphagic response is real. Sleep 31:927-933.
44. Kucewicz MT, Tricklebank MD, Bogacz R, Jones MW (2011). Dysfunctional prefrontal cortical network activity and interactions following cannabinoid receptor activation. J Neurosci 31:15560-15568.
45. Lan R, Liu Q, Fan P, Lin S, Fernando SR, McCallion D, et al. (1999). Structureactivity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J Med Chem 42:769-776.
46. Landsman RS, Burkey TH, Consroe P, Roeske WR, Yamamura HI (1997). SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur J Pharmacol 334:R1-R2.
47. Lange C, Luque I, Hervás M, Ruiz-Sanz J, Mateo PL, De la Rosa MA (2005). Role of the surface charges D72 and K8 in the function and structural stability of the cytochrome c from Nostoc sp. PCC 7119. FEBS J 272:3317-3327.
48. Laposky AD, Shelton J, Bass J, Dugovic C, Perrino N, Turek FW (2006). Altered sleep regulation in leptin-deficient mice. Am J Physiol Regul Integr Comp Physiol 290:R894-R903.
49. Lee SH, Seo HJ, Lee SH, Jung ME, Park JH, Park HJ, et al. (2008). Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity. J Med Chem 51:7216-7233.
50. McMahon LR, KoekW(2007). Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice. Eur J Pharmacol 569:70-76.
51. Megevand P, Quairiaux C, Lascano AM, Kiss JZ, Michel CM (2008). A mouse model for studying large-scale neuronal networks using EEG mapping techniques. Neuroimage 42:591-602.
52. Murillo-Rodríguez E, Sánchez-Alavez M, Navarro L, Martinez-González D, Drucker-Colín R, Prospéro-García O (1998). Anandamide modulates sleep and memory in rats. Brain Res 812:270-274.
53. Murillo-Rodríguez E, Cabeza R, Mendez-Díaz M, Navarro L, Prospéro-García O (2001). Anandamide-induced sleep is blocked by SR141716A, a CB1 receptor antagonist and by U73122, a phospholipase C inhibitor. Neuroreport 12:2131-2136.
54. Murillo-Rodríguez E, Millán-Aldaco D, Di Marzo V, Drucker-Colín R (2008). The anandamide membrane transporter inhibitor, VDM-11, modulates sleep and c-Fos expression in the rat brain. Neuroscience 157:1-11.
55. Pan X, Ikeda SR, Lewis DL (1998). SR 141716A acts as an inverse agonist to increase neuronal voltage-dependent Ca2 + currents by reversal of tonic CB1 cannabinoid receptor activity. Mol Pharmacol 54:1064-1072.
56. Pertwee RG (2005). Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 76:1307-1324.
57. Pivik RT, Zarcone V, Dement WC, Hollister LE (1972). Delta-9-tetrahydrocannabinol and synhexyl: effects on human sleep patterns. Clin Pharmacol Ther 13:426-435.
58. Platt B, Riedel G (2011). The cholinergic system, EEG and sleep. Behav Brain Res 221:499-504.
59. Randall PA, Vemuri VK, Segovia KN, Torres EF, Hosmer S, Nunes EJ, et al. (2010). The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behavior. Pharmacol Biochem Behav 97:179-184.
60. Riedel G, Davies SN (2005). Cannabinoid function in learning, memory and plasticity. Handb Exp Pharmacol 168:445-477.
61. Riedel G, Fadda P, McKillop-Smith S, Pertwee RG, Platt B, Robinson L (2009). Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice. Br J Pharmacol 156:1154-1166.
62. Robbe D, Montgomery SM, Thome A, Rueda-Orozco PE, McNaughton BL, Buzsaki G (2006). Cannabinoids reveal importance of spike timing coordination in hippocampal function. Nat Neurosci 9:1526-1533.
63. Robinson L, McKillop-Smith S, Ross NL, Pertwee RG, Hampson RE, Platt B, Riedel G (2008). Hippocampal endocannabinoids inhibit spatial learning and limit spatial memory in rats. Psychopharmacol 198:551-563.
64. Robinson L, Goonawardena AV, Pertwee RG, Hampson RE, Platt B, Riedel G (2010). WIN55,212-2 induced deficits in spatial learning are mediated by cholinergic hypofunction. Behav Brain Res 208:584-592.
65. Rubino T, Parolaro D (2011). Sexually dimorphic effects of cannabinoid compounds on emotion and cognition. Front Behav Neurosci 5:64.
66. Sam AH, Salem V, Ghatei MA (2011). Rimonabant: from RIO to Ban. J Obesity 2011:432607.
67. Santucci V, Fournier M, Worms P, Keane P, Biziere K (1989). Cerebral-activating (EEG) properties of two inverse agonists and of an antagonist at the benzodiazepine receptor in the rat. Naunyn-Schmiedeberg's Arch Pharmacol 340:93-100.
68. Santucci V, Storme JJ, Soubrie P, Le FG (1996). Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis. Life Sci 58:L103-L110.
69. Saper CB, Chou TC, Scammell TE (2001). The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci 24:726-731.
70. Schierenbeck T, Riemann D, Berger M, Hornyak M (2008). Effect of illicit recreational drugs upon sleep: cocaine, ecstasy and marijuana. Sleep Med Rev 12:381-389.
71. Sim-Selley LJ, Brunk LK, Selley DE (2001). Inhibitory effects of SR141716A on G-protein activation in rat brain. Eur J Pharmacol 414:135-143.
72. Sink KS, McLaughlin PJ,Wood JA, Brown C, Fan P, Vemuri VK, et al. (2008a). The novel cannabinoid CB(1) receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology 43:946-955.
73. Sink KS, Vemuri VK, Olszewska T, Makriyannis A, Salamone JD (2008b). Cannabinoid CB1 antagonists and dopamine antagonists produce different effects on a task involving response allocation and effort-related choice in food-seeking behavior. Psychopharmacology (Berl) 196:565-574.
74. Sokal DM, Benetti C, Girlanda E, Large CH (2008). The CB1 receptor antagonist, SR141716A, prevents high-frequency stimulation-induced reduction of feedback inhibition in the rat dentate gyrus following perforant path stimulation in vivo. Brain Res 1223:50-58.
75. Srivastava BK, Soni R, Joharapurkar A, Sairam KV, Patel JZ, Goswami A, et al. (2008). Bioisosteric replacement of dihydropyrazole of 4S-(-)-3-(4-chlorophenyl)-N-methyl-N'-[(4-chlorophenyl)-sulfonyl]-4-phenyl-4,5-dihydro-1Hpyrazole-1-caboxamidine (SLV-319) a potent CB1 receptor antagonist by imidazole and oxazole. Bioorg Med Chem Lett 18:963-968.
76. Tallarida RJ, Cowan A, Adler MW (1979). pA2 and receptor differentiation: a statistical analysis of competitive antagonism. Life Sci 25:637-654.
77. Uchiyama N, Kikura-Hanajiri R, Matsumoto N, Huang Z-L, Goda Y, Urade Y (2012). Effects of synthetic cannabinoids on electroencephalogram power spectra in rats. Forensic Sci Int 215:179-183.
78. Verty ANA, Evetts MJ, Crouch GJ, McGregor IS, Stefanidis A, Oldfield BJ (2011). The cannabinoid receptor agonist THC attenuates weight loss in a rodent model of activity-based anorexia. Neuropsychopharmacology 36:1349-1358.
79. Wright FL, Rodgers RJ (2013). Low dose naloxone attenuates the pruritic but not anorectic response to rimonabant in male rats. Psychopharmacology (Berl) 226:415-431.
80. Wu CH, Hung MS, Song JS, Yeh TK, Chou MC, Chu CM, et al. (2009). Discovery of 2-[5-(4-chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-ethyl-1H-pyrazol-3-yl]-1,5,5-trimethyl-1,5-dihydro-imidazol-4-thione (BPR-890) via an active metabolite. A novel, potent and selective cannabinoid-1 receptor inverse agonist with high antiobesity efficacy in DIO mice. J Med Chem 52:4496-4510.
81. Yamanaka A, Beuckmann CT, Willie JT, Hara J, Tsujino N, Mieda M, et al. (2003). Hypothalamic orexin neurons regulate arousal according to energy balance in mice. Neuron 38:701-713.